- Home
- TKNO vs DCTH Comparison
TKNO vs DCTH Comparison
Compare TKNO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- DCTH
- Stock Information
- Founded
- TKNO 1996
- DCTH 1988
- Country
- TKNO United States
- DCTH United States
- Employees
- TKNO N/A
- DCTH N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- DCTH Medical/Dental Instruments
- Sector
- TKNO Health Care
- DCTH Health Care
- Exchange
- TKNO Nasdaq
- DCTH Nasdaq
- Market Cap
- TKNO 390.7M
- DCTH 398.2M
- IPO Year
- TKNO 2021
- DCTH N/A
- Fundamental
- Price
- TKNO $8.07
- DCTH $14.31
- Analyst Decision
- TKNO Buy
- DCTH Strong Buy
- Analyst Count
- TKNO 2
- DCTH 4
- Target Price
- TKNO $5.00
- DCTH $22.25
- AVG Volume (30 Days)
- TKNO 324.6K
- DCTH 411.6K
- Earning Date
- TKNO 03-10-2025
- DCTH 11-08-2024
- Dividend Yield
- TKNO N/A
- DCTH N/A
- EPS Growth
- TKNO N/A
- DCTH N/A
- EPS
- TKNO N/A
- DCTH N/A
- Revenue
- TKNO $36,347,000.00
- DCTH $22,644,000.00
- Revenue This Year
- TKNO $3.47
- DCTH $1,605.13
- Revenue Next Year
- TKNO $12.07
- DCTH $111.67
- P/E Ratio
- TKNO N/A
- DCTH N/A
- Revenue Growth
- TKNO N/A
- DCTH 945.91
- 52 Week Low
- TKNO $1.16
- DCTH $3.70
- 52 Week High
- TKNO $9.72
- DCTH $14.47
- Technical
- Relative Strength Index (RSI)
- TKNO 49.91
- DCTH 70.27
- Support Level
- TKNO $7.15
- DCTH $12.14
- Resistance Level
- TKNO $8.53
- DCTH $12.98
- Average True Range (ATR)
- TKNO 0.75
- DCTH 0.77
- MACD
- TKNO -0.14
- DCTH 0.16
- Stochastic Oscillator
- TKNO 38.06
- DCTH 95.12
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.